- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Contrast-enhanced CT for PE poses no risk to neonatal thyroid function
A retrospective single-center study involving 350 pregnant women indicates that contrast-enhanced CT to diagnose suspected pulmonary embolism poses no risk to the thyroid function of neonats.
A retrospective single-center study involving 350 pregnant women indicates that contrast-enhanced CT to diagnose suspected pulmonary embolism poses no risk to the thyroid function of neonats.
Dr. T. Claire Alleyne and colleagues at the Women and Infants Hospital of Rhode Island in Providence retrospectively evaluated 350 pregnant women who underwent multislice CT for suspected PE at the hospital from 2004 to 2008. Public health screening records of their newborn infants were examined for T4 thyroxine and thyroid-stimulating hormone.
Contrast dosage administered to the women ranged from 100 cc of 300 mgI/mL of iohexol (Omnipaque) to 150 cc of 350 mgI/mL of the agent.
Alleyne and colleagues found that all newborns had T4 levels deemed appropriate for their gestational age. One newborn, however, had normal T4 but abnormal thyroid-stimulating hormone recorded on the second day of life. The child's TSH level normalized four days later.
The finding led Alleyne to conclude that fears about iodinated contrast media and newborn thyroid function are very likely unfounded. The study's results can be explained by the short-term exposure involved with the contrast-enhanced procedure, the rapid elimination of contrast by maternal kidneys, the physical characteristics of iohexol, and the long duration between exposure and newborn screening, she said.
The findings are limited by the single-center nature of the trial and possibly by undersampling for a postnatal syndrome that affects only one in 20,000 live births, Alleyne said. Still, a literature search associated with the trial suggests that it involved more subjects than any other study to consider this issue, she said.
AI Facilitates Nearly 83 Percent Improvement in Turnaround Time for Fracture X-Rays
December 19th 2023In addition to offering a 98.5 percent sensitivity rate in diagnosing fractures on X-ray, an emerging artificial intelligence (AI) software reportedly helped reduce mean turnaround time on X-ray fracture diagnosis from 48 hours to 8.3 hours, according to new research presented at the Radiological Society of North America (RSNA) conference.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
Can an Emerging PET Radiotracer Enhance Detection of Prostate Cancer Recurrence?
December 14th 2023The use of 68Ga-RM2 PET/MRI demonstrated a 35 percent higher sensitivity rate than MRI alone for the diagnosis of biochemical recurrence of prostate cancer, according to research recently presented at the Radiological Society of North America (RSNA) conference.
RSNA 2020: Addressing Healthcare Disparities and Access to Care
December 4th 2020Rich Heller, M.D., with Radiology Partners, and Lucy Spalluto, M.D., with Vanderbilt University School of Medicine, discuss the highlights of their RSNA 2020 session on health disparities, focusing on the underlying factors and challenges radiologists face to providing greater access to care.
Can AI Improve Detection of Extraprostatic Extension on MRI?
December 4th 2023Utilizing a deep learning-based AI algorithm to differentiate between diagnostic and non-diagnostic quality of prostate MRI facilitated a 10 percent higher specificity rate for diagnosing extraprostatic extension on multiparametric MRI, according to research presented at the recent RSNA conference.
Study: Regular Mammography Screening Reduces Breast Cancer Mortality Risk by More than 70 Percent
November 30th 2023Consistent adherence to the five most recent mammography screenings prior to a breast cancer diagnosis reduced breast cancer death risk by 72 percent in comparison to women who did not have the mammography screening, according to new research findings presented at the annual Radiological Society of North America (RSNA) conference.
